Biogen Idec acquires Neurimmune subsidiary
Links shared publicly online about this topic.
- 639total visits
Biogen Idec acquires Neurimmune subsidiary
Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43.
View full resource at news-medical.net
Tags: Nervous System, Parkinson's Disease, Disease and Condition, Biogen Idec, disease
Most Recently Shared on December 21, 2010 at 10:30 am By:
Parkinson's Disease: Biogen Idec acquires Neurimmune subsidiary: Biogen Idec and Neurimmune Holding AG today ann... http://bit.ly/eguDEu
Biogen Idec And Neurimmune Announce Agreement On Three Neurodegenerative Disease Programs
medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) and Neurimmune Holding AG have announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunother” View full resource at medicalnewstoday.com
Most Recently Shared on December 22, 2010 at 2:05 pm By:
MNT Pharma News Pharma and Health News
Biogen Idec And Neurimmune Announce Agreement On Three Neurodegenerative Disease Programs http://mnt.to/3Pp8 #pharma #pharmaceutical
Advertisement
